Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses

NCT01170936 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Urticaria
Vasculitis

Interventions

DRUG: canakinumab

Sponsor

Charite University, Berlin, Germany

Collaborators

[object Object]